| Literature DB >> 29277328 |
Yunfeng Zhou1, Jingwei Yu1, Jia Liu1, Rong Cao2, Wen Su1, Sha Li3, Shiqi Ye1, Chenggang Zhu4, Xiaolin Zhang4, Hu Xu5, Hua Chen5, Xiaoyan Zhang6, Youfei Guan7.
Abstract
Angiotensin II (AngII) plays an important role in the pathogenesis of hypertension and associated renal injuries. To elucidate the molecular mechanism by which AngII induces renal damage, we found that AngII infusion significantly induced CYP4A14 expression in renal proximal tubule cells (RPTCs) with marked increases in blood pressure and proteinuria. Renal production of the major CYP4A metabolite, 20-HETE, was also significantly increased in the AngII-treated mice. Compared to wild-type (WT) mice, CYP4A14 knockout (CYP4A14-/-) mice exhibited significantly lower levels of blood pressure, renal 20-HETE production, proteinuria and renal fibrosis following AngII infusion. Furthermore, AngII-induced renal expression of profibrotic genes and proinflammatory genes was significantly attenuated in CYP4A14-/- mice. In vitro studies using cultured RPTCs demonstrated that AngII significantly induced CYP4A14 expression and 20-HETE production via the MAPK signaling pathway. AngII treatment increased TGF-β and collagen expression, which was attenuated by the CYP4A inhibitor, TS-011. Moreover, 20-HETE treatment potently induced CYP4A14 expression and TGF-β and collagen levels. Collectively, these findings suggest that attenuated renal fibrosis in AngII-treated CYP4A14-/- mice may result from both reduced systemic blood pressure and renal 20-HETE production. Therefore, CYP4A14 may represent a useful target for the treatment of AngII-associated renal damage.Entities:
Keywords: Angiotensin II; CKD; Cytochrome P450 4A14; Fibrosis; Inflammation
Mesh:
Substances:
Year: 2017 PMID: 29277328 DOI: 10.1016/j.bbadis.2017.12.028
Source DB: PubMed Journal: Biochim Biophys Acta Mol Basis Dis ISSN: 0925-4439 Impact factor: 5.187